单一靶向转铁蛋白受体2的策略可纠正炎症性贫血与慢性肾脏病贫血小鼠模型的铁代谢和红细胞生成缺陷
研究在无菌性炎症伴正常肾功能小鼠及慢性肾脏病小鼠中,通过选择性敲除造血或肝脏转铁蛋白受体2(Tfr2),观察对贫血、红细胞生成及铁代谢的影响。结果显示同时敲除造血和肝脏Tfr2可刺激红细胞生成并增加铁供给,从而在整个实验方案期间改善慢性肾脏病小鼠贫血,且不增加血清促红细胞生成素水平。
要点
- 造血Tfr2缺失可改善正常肾功能炎症小鼠贫血,不升高血清EPO。
- 慢性肾脏病小鼠仅造血Tfr2缺失改善贫血短暂,因铁可用性有限。
- 同时敲除造血和肝脏Tfr2可改善慢性肾脏病小鼠贫血至整个方案结束。
核心结论
- 同时靶向造血和肝脏Tfr2可能成为平衡红细胞生成刺激与铁增加的治疗选择,且不影响EPO水平。
研究设计与样本
- 研究为小鼠模型实验,包括无菌性炎症伴正常肾功能小鼠和慢性肾脏病小鼠,采用选择性造血或肝脏Tfr2敲除。
主要发现
- 造血Tfr2缺失改善正常肾功能炎症小鼠贫血,促进EPO反应性和红细胞生成,不增加血清EPO水平。
- 慢性肾脏病小鼠中造血Tfr2缺失对红细胞生成有类似效应,但贫血改善短暂,因铁可用性有限。
- 仅下调肝脏Tfr2增加铁水平对贫血影响较小。
- 同时敲除造血和肝脏Tfr2足以在整个实验方案期间改善贫血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is a common complication of systemic inflammation. Proinflammatory cytokines both decrease erythroblast sensitivity to erythropoietin (EPO) and increase the levels of the hepatic hormone hepcidin, sequestering iron in stores and causing functional iron deficiency. Anemia of chronic kidney disease (CKD) is a peculiar form of anemia of inflammation, characterized by impaired EPO production paralleling progressive kidney damage. Traditional therapy based on increased EPO (often in combination with iron) may have off-target effects due to EPO interaction with its non-erythroid receptors. Transferrin Receptor 2 (Tfr2) is a mediator of the iron-erythropoiesis crosstalk. Its deletion in the liver hampers hepcidin production, increasing iron absorption, whereas its deletion in the hematopoietic compartment increases erythroid EPO sensitivity and red blood cell production. Here, we show that selective hematopoietic Tfr2 deletion ameliorates anemia in mice with sterile inflammation in the presence of normal kidney function, promoting EPO responsiveness and erythropoiesis without increasing serum EPO levels. In mice with CKD, characterized by absolute rather than functional iron deficiency, Tfr2 hematopoietic deletion had a similar effect on erythropoiesis but anemia improvement was transient because of limited iron availability. Also, increasing iron levels by downregulating only hepatic Tfr2 had a minor effect on anemia. However, simultaneous deletion of hematopoietic and hepatic Tfr2, stimulating erythropoiesis and increased iron supply, was sufficient to ameliorate anemia for the entire protocol. Thus, our results suggest that combined targeting of hematopoietic and hepatic Tfr2 may be a therapeutic option to balance erythropoiesis stimulation and iron increase, without affecting EPO levels.
引用
- Olivari V, Di Modica SM, Lidonnici MR, et al. A single approach to targeting transferrin receptor 2 corrects iron and erythropoietic defects in murine models of anemia of inflammation and chronic kidney disease. Kidney Int. 2023. PMID: 36990212. doi:10.1016/j.kint.2023.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。